Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

261

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

December 31, 2018

Conditions
Herpes Genitalis
Interventions
BIOLOGICAL

VCL-HB01

Investigational Product

OTHER

Phosphate-buffered saline

Placebo

Trial Locations (15)

14609

Rochester Clinical Research, Inc., Rochester

27599

University of North Carolina (UNC) Institute of Global Health and Infectious Diseases, Chapel Hill

33024

QPS Broward Research, Hollywood

33143

QPS Miami Research Associates, South Miami

33409

Comprehensive Clinical Trials, LLC, West Palm Beach

37203

Clinical Research Associates, Inc., Nashville

40509

Central Kentucky Research Associates, Inc., Lexington

46202

Indiana University Infectious Disease Research, Indianapolis

60612

University of Illinois, Chicago

64114

The Center for Pharmaceutical Research, Kansas City

67207

Heartland Research Associates, LLC, Wichita

84132

University of Utah School of Medicine - Division of Infectious Diseases, Salt Lake City

92108

Medical Center for Clinical Research, San Diego

98104

University of Washington, Seattle

35294-2050

Alabama Vaccine Research Clinic at University of Alabama at Birmingham, Birmingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Vical

INDUSTRY

NCT02837575 - Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine | Biotech Hunter | Biotech Hunter